P63 is a p53 family member involved in multiple facets of biology, including embryonic development, cell proliferation, differentiation, survival, apoptosis, senescence and aging. The p63 gene encodes multiple protein isoforms either with (TAp63) or without (DNp63) the N-terminal transactivation domain. Amounting evidence suggests that p63 can function as a tumor suppressor, yet the precise molecular mechanisms, and particularly the specific roles of TAp63 and DNp63 in cancer progression, are still largely unclear. Here, we demonstrated that DNp63a, the predominant isoform expressed in epithelial cells and squamous cell carcinomas, inhibits cell invasion. Affymetrix gene expression profiling, combined with gain-and lossof-function analyses and chromatin immunoprecipitation, indicated that cluster of differentiation 82 (CD82), a documented metastasis suppressor, is a direct transcriptional target of DNp63a. Expression of DNp63a inhibited outgrowth in Matrigel and cancer cell invasion, which was largely reversed by specific ablation of CD82. Conversely, DNp63a knockdown led to increased cell invasion, which was reversed by ectopic expression of CD82. Moreover, inhibition of glycogen synthase kinase-3b (GSK3b) by either pharmacological inhibitors or by RNA interference resulted in the downregulation of DNp63a and CD82 expression, concomitant with increased cell invasion, independently of b-catenin. Furthermore, decreased expression of p63 and CD82 is correlated with cancer progression. Taken together, this study reveals that DNp63a upregulates CD82 to inhibit cell invasion, and suggests that GSK3b can regulate cell invasion by modulating the DNp63a-CD82 axis.
The p63 gene is a member of the p53 family that is expressed as multiple isoforms with pleiotropic functions. TAp63 isoforms contain an N-terminal transactivation domain homologous to that of p53, whereas DNp63 isoforms bear no resemblance to the p53 transactivation domain. Alternative splicing generates five C termini (a, b, g, d and e) for a total of 10 isoforms described to date. All p63 isoforms share the same DNA-binding domain (DBD) and oligomerization domain. In addition, p63a isoforms contain a sterile alpha motif (SAM), which is important for protein-protein interaction, and a transactivation inhibitory domain. TAp63 and DNp63 proteins have important roles in the regulation of multiple processes, including cell proliferation, survival, apoptosis, differentiation, senescence and aging.
1,2 Heterozygous autosomal mutations in the p63 gene are associated with human developmental diseases, such as EEC (ectrodactyly ectodermal dysplasia clefting) and AEC (ankyloblepharonectodermal dysplasia clefting) syndromes, which are characterized by orofacial and limb malformations. 3, 4 More marked phenotypes are found in p63-null mice, which succumb to early postnatal lethality owing to the lack of stratified epithelia, limb truncations and craniofacial defects. 5, 6 TAp63 isoforms are highly expressed in oocytes, where they are crucial for inducing apoptosis upon DNA damage independently of p53. 7, 8 On the other hand, DNp63a is the predominant isoform in the proliferative, basal compartment of stratified epithelia, and has been shown to be essential for maintaining the regenerative potential of epithelial stem cells. 9, 10 Unlike p53, mutations in the p63 gene are rarely found in human cancers. 11, 12 Rather, DNp63a is usually overexpressed in a wide range of human squamous cell carcinomas (SCCs). 13, 14 Multiple studies have described oncogenic functions for DNp63a, such as inhibition of TAp73-mediated apoptosis in SCC 15, 16 and cooperation with Ras to induce tumor formation in mouse xenografts. 17 However, accumulating evidence strongly suggests that p63 proteins have an important role as metastasis suppressors. For example, p53 þ / À ;p63 þ / À mice display a much higher rate of metastasis than p53 þ / À mice, 18 and TAp63-deficient mice develop highly metastatic cancers. 19 Moreover, disrupting p63 expression results in the upregulation of mesenchymal genes and in enhanced cell motility in tissue culture. 20, 21 Taken together, these studies strongly implicate p63 as a metastasis inhibitor. However, the molecular mechanisms underlying these effects are not yet fully understood.
Cluster of differentiation 82 (CD82; also known as KAI1) is a transmembrane protein belonging to the tetraspanin superfamily. Tetraspanins form specialized membrane microdomains believed to interact with other transmembrane proteins and microdomains, thus forming signaling networks involved in a wide variety of biological processes, including cell migration, fusion, adhesion and proliferation. 22 CD82 was initially assigned a role in metastasis suppression by a genetic screen for metastasis-suppressing genes in prostate cancer. 23 CD82 has been shown to downregulate p130Cas, thereby preventing Rac1 activation and leading to decreased cell migration, 24 and to inhibit EGFR/Her2-induced migration by preventing ligand binding and heterodimerization. 25, 26 Furthermore, p53 binds the CD82 promoter and promotes its transcription, thus suggesting a tumor suppressor role for CD82. 27, 28 Glycogen synthase kinase 3b (GSK3b) is a serine/ threonine kinase that is involved in multiple cellular functions, including metabolism, cell growth and proliferation, differentiation and apoptosis. 29 GSK3b phosphorylates the cotranscriptional activator b-catenin, thus targeting it for ubiquitination and degradation. Activation of Wnt signaling inhibits GSK3b activity, leading to nuclear b-catenin accumulation and increased gene expression, including oncogenes such as cyclin D1 and Myc. 30 GSK3b has also been recognized as an important player in the regulation of epithelial-to-mesenchymal transition (EMT) by targeting Snail to proteasomal degradation. 31 Snail induces EMT by repressing E-cadherin expression, thereby promoting metastasis. 32 In this study, we found that DNp63a inhibits cell invasion without significantly affecting the expression of EMT markers. We identified the metastasis suppressor CD82 as a direct DNp63a transcriptional target, and found that CD82 has an important role in mediating inhibition of cell invasion by DNp63a. Moreover, we discovered that silencing GSK3b results in the downregulation of both DNp63a and CD82, leading to increased cell invasion.
Results

DNp63a inhibits Matrigel outgrowth and invasion of human Hs-578T cells.
To analyze the role of p63 in cancer development, we used Oncomine, an online cancer-profiling database, to investigate a potential correlation between p63 expression and cancer progression. As shown in Figures 1a-d , p63 expression was significantly decreased in biopsy samples from metastatic lesions, compared with samples from primary tumors in breast, prostate, lung cancer and melanoma. Moreover, p63 expression was decreased progressively in breast, bladder and prostate cancers of higher pathological grade or stage (Figures 1e-i) . These data clearly indicate that p63 downregulation correlates with cancer progression from primary tumor to metastatic dissemination.
As DNp63a is the predominant protein isoform expressed in the majority of epithelial and cancer cells, 14, 33, 34 we investigated the role of DNp63a in cell invasion. We chose human breast cancer Hs-578T cells because they lack detectable p63 protein expression, are highly invasive and exhibit branching morphogenesis in the Matrigel. 35 We infected Hs-578T cells with retrovirus expressing either wild-type (WT) DNp63a or a disease-derived mutant. DNp63a(C306R) harbors a point mutation in the DBD that impairs DNA binding and is associated with EEC syndrome, 3 whereas C526W is a point mutation in the SAM domain that affects protein-protein interaction and is associated with AEC syndrome. 4 Control Hs-578T cells exhibited characteristic outgrowth and branching morphogenesis in the Matrigel, whereas the expression of WT DNp63a markedly inhibited outgrowth. By contrast, expression of either mutant DNp63a had little effect on Matrigel outgrowth (Figure 2a ). In addition, WT DNp63a, but not the mutant derivatives, significantly inhibited cell invasion (Figure 2b and Supplementary Figure S1a) . To examine whether DNp63a could inhibit cell invasion in other cell types, we analyzed human non-small-cell lung carcinoma H1299 cells and human lung adenocarcinoma A549 cells stably expressing WT DNp63a. Consistently, DNp63a markedly inhibited cell invasion in both H1299 and A549 cells (Figure 2b and Supplementary Figure S1b) . Taken together, these results indicate that ectopic DNp63a expression inhibits cell invasion, and that both direct DNA binding and interaction with cellular proteins via the SAM domain are required for DNp63a to exert this function. Moreover, no significant changes in the expression of classic EMT markers (i.e. E-cadherin, N-cadherin and vimentin) were observed in cells expressing DNp63a (Figure 2c ). These results suggest that DNp63a expression inhibits cell invasion independently of modulation of typical EMT markers. We further investigated whether DNp63a expression affected apoptosis or cell proliferation. DNp63a expression had little effect on cell proliferation (Figure 2d ) and on apoptosis, as assessed by cleaved PARP and cleaved caspase-3 levels ( Figure 2c ).
CD82 is upregulated by WT DNp63a, but not by its two disease-associated mutants. To identify molecular mechanisms by which DNp63a inhibits cell invasion, we profiled gene expression of Hs-578T cells expressing WT or mutant DNp63a. As shown in Figure 3a and Supplementary Figure S2a , DNp63a expression upregulated 136 genes and downregulated 77 genes. Out of these genes, 17 were also upregulated and 4 downregulated by DNp63a(C306R), suggesting that, in some instances, DNp63a may act as a cotranscriptional regulator independently of direct DNA binding. Likewise, DNp63a(C526W) upregulated 16 genes and downregulated 4 genes overlapping with WT DNp63a, suggesting that protein-protein interaction via the SAM domain is required for the regulation of yet another subset of genes. In addition, WT and both mutant DNp63a proteins upregulated 13 overlapping genes and downregulated 2 overlapping genes to a similar extent. These data suggest that both direct DNA binding and interaction via the SAM domain may be dispensable for the regulation of certain genes. On the other hand, both DNp63a(C306R) and DNp63a(C526W) regulated a unique set of non-overlapping genes. Of note, our microarray analyses showed upregulation of several previously published p63 downstream targets (Supplementary Table S1 ).
Ontological analysis of genes that were affected by WT, but not mutant DNp63a, revealed multiple biological functions, including cell communication, development, differentiation, immune system processes, response to stress, regulation of apoptosis, cell proliferation and regulation of cell cycle (Supplementary Tables S2 and S3 ). In particular, we found a subset of genes involved in cell adhesion or motility/ migration. Of these genes, CD82 was upregulated by WT DNp63a, but not by the mutant derivatives (Supplementary Figure S2b) . CD82 functions as a metastasis suppressor in a variety of human cancers, 36 thus making it a likely candidate for acting as an effector of DNp63a function in inhibiting cell migration and invasion. We confirmed CD82 induction by WT DNp63a in Hs-578T, H1299 and A549 cells via quantitative polymerase chain reaction (Q-PCR) (Figure 3b ) and western blotting (Figure 3c ). These results suggest that DNp63a regulates CD82 at the transcriptional level, and that this effect requires an intact DBD and SAM domain.
Next, we explored the clinical relevance of DNp63a-mediated upregulation of CD82. We used Oncomine to analyze CD82 and p63 expression. In prostate cancer and melanoma, expression of both p63 and CD82 was decreased in metastatic lesions compared with primary tumor samples (Figure 3d) , and further analysis revealed a clear positive correlation between p63 and CD82 expression (Figure 3e ). Taken together, these observations indicate that decreased p63 and CD82 expression is correlated with metastatic cancer progression.
DNp63a-mediated inhibition of cell invasion requires CD82. To investigate the role of CD82 in DNp63a-induced inhibition of cell migration and invasion, we expressed Figure S3a ). We next examined whether DNp63a-mediated inhibition of cell invasion requires CD82 by ablating CD82 in Hs-578T, H1299 and A549 cells stably expressing DNp63a ( Figure 4c ). As shown in Figure 4d and Supplementary Figures S3b-g, DNp63a expression markedly inhibited cell invasion, whereas silencing CD82 significantly rescued the invasive phenotype of these cells. Moreover, reintroduction of CD82 into Hs-578T and H1299 cells with concomitant DNp63a expression and CD82 ablation effectively reverted cell invasion to levels comparable to DNp63a expression alone (Supplementary Figures S4a and b) . Taken together, these data strongly suggest that CD82 is an important downstream mediator of DNp63a in the regulation of cell invasion.
DNp63a is an endogenous regulator of CD82 in the regulation of cell invasion. We next examined whether endogenous DNp63a affects CD82 expression by ablating pan-p63 isoforms in human-immortalized keratinocyte HaCaT, head and neck SCC FaDu and non-transformed mammary epithelial MCF-10A cells, all of which express DNp63a as the major p63 isoform. Silencing p63 led to decreased CD82 protein levels, suggesting that DNp63a is a critical regulator of CD82 expression ( Figure 5a ). To examine whether CD82 protein stability is affected by p63 ablation, we 
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ΔNp63α Log2 median-centered CD82 expression Log2 median-centered TP63 expression Figure 3 DNp63a upregulates CD82 expression. Stable Hs-578T cells expressing WT murine DNp63a (WT), a mutant derivative (C306R or C526W), or a vector control (C) as described in Figure 2 were used. (a) Stable cells were subjected to gene expression profiling using Affymetrix human genome U133A 2.0 arrays in two independent arrays. A P-value lesser than 0.05 was used as the cutoff for significance, and genes exhibiting Z2-fold changes compared with the vector control were selected (also see Supplementary Figure S1 and Supplementary Tables S1-3 . Statistical significance was assessed by Pearson's correlation coefficient (r) followed by a two-tailed probability test (P-value)
Next, we examined the effect of DNp63a ablation on cell invasion. Silencing DNp63a in FaDu and MCF-10A cells led to increased cell invasion (Figure 6a and Supplementary Figure  S5a) , as well as a marked decrease in cell proliferation (Figure 6b ), in keeping with previous reports showing the importance of DNp63a for epithelial and SCC cell proliferation and survival. 16, 37 To examine whether CD82 induction by DNp63a is responsible for mediating the function of DNp63a in inhibiting cell invasion, we ablated p63 expression and concomitantly expressed CD82 in FaDu and MCF-10A cells (Figure 6c) . Again, p63 knockdown markedly induced cell invasion, whereas concomitant CD82 expression significantly reverted cell invasion (Figure 6d and Supplementary Figure  S5b) , indicating that CD82 is, at least partly, responsible for DNp63a-mediated regulation of cell invasion.
Inhibition of GSK3 activity reduces p63 mRNA and protein levels, and promotes cell invasion. We investigated potential upstream signaling mechanisms that could influence the DNp63a-CD82 pathway in cell invasion. We observed that when HaCaT and FaDu cells were treated with a GSK3 inhibitor, 6-bromoindirubin-3 0 -oxime (BIO), DNp63a and CD82 expression was significantly reduced (Figures 7a  and b) . To confirm the specificity of this inhibition, we silenced GSK3b expression, which led to a decrease in both DNp63a and CD82 expression in HaCaT and FaDu cells (Figure 7c ). It has been reported that CD82 can be downregulated by a b-catenin-reptin complex, thereby increasing the metastatic potential in prostate cancer. 38 As GSK3b is an important negative regulator of b-catenin, we investigated whether the effect of GSK3b inhibition on DNp63a and CD82 is mediated (Figure 7f ). Hence, these data indicate that GSK3b regulates DNp63a expression independently of b-catenin, and suggest that CD82 downregulation upon GSK3b inhibition is likely mediated by downregulated DNp63a, rather than as a result of accumulated b-catenin.
GSK3b ablation promotes cancer cell invasion, which is overcome by CD82 expression. As it has been shown that GSK3b can inhibit cell migration, 31 we examined whether CD82 has a role in GSK3b-mediated inhibition of cell invasion. Thus, we silenced GSK3b expression and reintroduced CD82 ectopically in FaDu cells (Figure 8a ). While GSK3b knockdown markedly promoted cell invasion, concomitant CD82 expression partially, but significantly, reverted cell invasion to lower levels ( Figure 8b and Supplementary Figure S5c) . These findings indicate that the DNp63a-CD82 pathway is regulated by GSK3b, which may contribute to GSK3b inhibitory function in cancer progression.
Discussion
DNp63a has been shown to have an important role in the regulation of cell proliferation, survival and differentiation. In this study, we showed that DNp63a functions as an inhibitor of cancer cell invasion via upregulation of CD82, a documented metastasis repressor. First, we showed that ectopic DNp63a potently inhibits cell invasion and branching morphogenesis in Matrigel, whereas silencing DNp63a markedly promotes cell invasion. Second, we identified CD82 as a direct DNp63a transcriptional target gene, and demonstrated that CD82 is critical in DNp63a-mediated regulation of cell invasion. Third, inhibition of GSK3b leads to a significant downregulation of both DNp63a and CD82 expression independently of b-catenin. Finally, GSK3b ablation results in increased cell invasion, which is significantly reverted by CD82 expression. Although DNp63a lacks a p53-homologous transactivation domain, the unique 14 N-terminal residues in DNp63 isoforms possess transactivation activity. 39 Here, we showed that ectopic DNp63a expression regulated a specific set of genes, many of which were unaffected by mutant derivatives harboring either EEC-or AEC-associated mutations, implying that these mutations result in the loss of normal transactivation activity. This is consistent with a previous study reporting that DNp63a mutations in the DBD and in the SAM domain are unable to transactivate skin-specific promoters. 40 We also found that DNp63a(C306R) and DNp63a(C526W) can each regulate a unique set of genes. Interestingly, mutant p53 proteins have been shown to regulate gene expression differentially and to acquire prometastatic functions via multiple molecular mechanisms. 41 Similarly, mutant p63 proteins could gain new functions. For example, an R298Q mutation associated with ADULT (acro-dermato-ungual-lacrimal-tooth) syndrome has been shown to increase DNp63g transactivation capacity, 42 and G530V and Q536L mutations in the SAM domain have been shown to increase DNp63a binding to the transcription factor SATB2, and to render TAp63a more susceptible to inhibition by SATB2 on transactivation of a PERP gene reporter. 43 Interestingly, we demonstrated that DNp63a strongly inhibits cell invasion, yet we did not detect significant changes in classical epithelial or mesenchymal markers in cells with altered motility. Notably, the specific role of DNp63a in EMT is still unclear. While it has been reported that loss of DNp63a . Puromycin-resistant cells were subjected to western blotting (c), or transwell cell invasion assays (d), as described previously. Results from cell invasion assays were quantitated and presented as mean and S.E. from three independent experiments. **Po0.01
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J Wu et al results in increased N-cadherin expression in urothelial carcinoma 21 and that enforced DNp63 expression in prostate cancer cells inhibits ZEB1 (a major positive regulator of EMT) expression, 44 it has also been shown that DNp63a does not affect either N-cadherin or E-cadherin in SCC. 45, 46 These findings suggest that DNp63a-mediated regulation of cell invasion and metastasis could involve EMT in some cases, whereas it may also be different and independent from classical EMT in other cases.
We found that inhibition of GSK3b decreases DNp63a expression and promotes cell invasion independently of b-catenin. GSK3b has been shown to inhibit EMT by targeting Snail for proteasomal degradation, thus releasing E-cadherin from transcriptional repression by Snail and promoting HaCaT and FaDu cells were infected with two independent lentivirus shRNA against GSK3b (sh3b-1 and sh3b-2) or a control vector (Ctrl), and selected by puromycin resistance. Whole-cell lysates were subjected to western blot analysis. (d and e) HaCaT cells were transfected with siRNA specific for b-catenin (sib-cat) or a control siRNA (siCtrl). Forty-eight hours after transfection, cells were collected and subsequently subjected to Q-PCR analyses for DNp63a, CD82 and b-catenin gene expression (d), or to western blotting (e). Results from Q-PCR are presented as mean and S.E. from two independent experiments performed in triplicate. (f) Forty-eight hours after FaDu cells were transfected with siRNA against b-catenin (sib-cat) or a control siRNA (siCtrl), cells were treated with 5 mM BIO for an additional 24 h. Whole-cell lysates were subjected to western blot analysis, as shown metastasis. 31, 32 Snail has been shown to also promote cell invasion by downregulating DNp63a in human SCC via suppression of C/EBPa-dependent transcription. 46 Moreover, clinical studies showed that increased Snail levels correlate with DNp63a downregulation in SCC. 47 Thus, these results suggest multiple and complex signaling pathways in the regulation of DNp63a (Figure 8d) .
By analyzing clinical data, we found that p63 expression decreases as cancers become more aggressive. In particular, metastatic lesions frequently exhibit lower p63 levels than primary tumors, consistent with previous studies showing that p63 expression is decreased in advanced cases of urothelial, breast and bladder carcinomas. [48] [49] [50] As gene expression data reflect levels of all p63 isoforms, the specific contribution of each p63 isoform to cancer progression remains unclear. This is particularly important as it has been reported that both homozygous and heterozygous TAp63-specific knockout mice develop spontaneous tumors that are highly metastatic. 19 In addition, p53 may have a critical role in TAp63-mediated regulation of metastasis, as mutant p53 has been shown to induce metastasis, at least partly, by inhibiting TAp63. 51, 52 More recently, it was shown that TAp63 deletion in a mouse model of KRAS(G12D)-driven pancreatic cancer does not increase metastasis, whereas simultaneous p53 and TAp63 deletion results in aggressive tumors with higher metastatic potential, 53 suggesting that the antimetastatic effects of TAp63 may depend on p53 status. Notably, it has been shown that DNp63a expression in epithelial cells is 10-fold to several hundred-fold higher than TAp63 expression. 20, 37, 54, 55 Thus, any significant changes in p63 gene expression observed in clinical studies of carcinoma samples should predominantly reflect changes in DNp63a levels, which would strongly implicate that DNp63a has a role in inhibition of cancer metastasis. In support of this notion, independent groups have shown that enforced expression of DNp63a in spindle carcinoma or prostate cancer cells inhibits metastasis to the lungs when injected intravenously into recipient mice. 44, 51 Recently, we showed that DNp63a, but neither TAp63 nor DNp63g, can revert invasion in cells with pan-p63 ablation. 56 In addition, we showed that DNp63a deficiency in mutant Her2/Neu-transformed mammary epithelial cells markedly enhances metastatic dissemination in nude mice. 56 Taken together, these studies strongly suggest that DNp63a is likely responsible for inhibiting cell invasion and metastasis in cancers of epithelial origin. Clearly, given the great variation in p63 protein expression between cell types, it is likely that the specific function of each p63 isoform is cell context-dependent.
Similar to DNp63a, CD82 downregulation has been found to be clinically associated with metastasis in a variety of cancers. [57] [58] [59] [60] Analogously, CD82 overexpression has been shown to suppress metastatic spread in animal models of melanoma, breast and prostate tumors. [61] [62] [63] We revealed that CD82 is an important mediator of DNp63a function toward inhibiting cell invasion and metastasis. First, DNp63a directly transactivates CD82 expression independently of p53 status, as silencing of DNp63a reduces CD82 expression in both MCF-10A (WT p53) and FaDu cells (truncated p53 and DNAbinding deficient p53[R248L] 64 ). Second, CD82 is an important mediator of DNp63a-mediated inhibition of cell invasion, as silencing of CD82 significantly reverses inhibition of cell invasion induced by ectopic DNp63a expression. Conversely, ectopic CD82 expression can largely revert enhanced cell invasion elicited by DNp63a ablation. However, rescuing by CD82 is incomplete, suggesting that CD82 is an important player, but not the sole effector mediating DNp63a function in cell invasion. Third, we found a significant correlation between DNp63a and CD82 expression in prostate cancer and melanoma. Taken together, these data suggest that CD82 regulation by DNp63a may have a clinically relevant and likely important role in the regulation of cancer metastasis.
It is now clear that DNp63a regulates multiple genes involved in cell migration and invasion. For example, silencing DNp63a in SCC cells has been shown to upregulate genes involved in cell motility, such as N-cadherin, L1 adhesion molecule and Wnt-5A. 20 DNp63a has also been shown to inhibit invasion via induction of Id-3 expression, which subsequently inhibits Ets-1-mediated MMP2 transcription. 45 More recently, we showed that DNp63a negatively regulates Erk2 signaling by upregulating MAP kinase phosphatase 3 expression to inhibit cancer cell migration, invasion and metastasis. 56 Moreover, here we demonstrated that inhibition of GSK3b impacts on the DNp63a-CD82 axis in the regulation of cell invasion. Thus, DNp63a seems to act as an integrator of multiple signaling pathways that impact on cell migration and invasion. (a and b) FaDu cells were infected with lentivirus expressing shRNA against GSK3b (sh3b-1) or a control (shC), and subsequently infected with recombinant retrovirus expressing either CD82 or a vector control (c). Puromycin-resistant cells were subjected to western blotting (a), or cell invasion assays (b), as described previously. Results from cell invasion assays were quantitated and presented as means and S.E. from three independent experiments. (c) A working model for DNp63a inhibition of cell invasion via CD82 and a role for GSK3b signaling. DNp63a upregulates CD82 expression, leading to the inhibition of cell invasion and cancer metastasis. GSK3b is important for DNp63a expression, either through an unidentified mechanism (as in the case of this study) or through the downregulation of Snail, which inhibits DNp63a expression via Snail-mediated suppression of C/EBP. 46 GSK3b also inhibits EMT by targeting Snail to proteasomal degradation, thereby suppressing cell invasion and cancer metastasis P63 inhibits cell invasion via CD82 J Wu et al
Materials and Methods
Cell culture, drug treatment and proliferation analysis. Human non-transformed mammary epithelial MCF-10A cells were maintained in 1 : 1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium with reduced Ca 2 þ (0.04 mM; Invitrogen Inc., Carlsbad, CA, USA), 20 ng/ml epidermal growth factor (Invitrogen), 100 ng/ml cholera toxin (Sigma, St. Louis, MO, USA), 10 mg/ml insulin (Sigma), 500 ng/ml (95%) hydrocortisone (Sigma) and 5% of Chelex-treated horse serum (Invitrogen). Human-immortalized keratinocyte HaCaT and head and neck SCC FaDu cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS; Invitrogen). Human breast cancer Hs-578T cells were cultured in DMEM supplemented with 10% FBS and 10 mg/ml insulin. All cells were grown in media containing 1% penicillin-G/ streptomycin sulfate at 37 1C in a humidified incubator under 5% CO 2 . For cell proliferation analysis, equal numbers of cells were seeded and grown under normal growth conditions. Every 24 h, cells were counted with a hemacytometer.
Plasmid construction, viral infections and RNA interference. To generate pMSCV-DNp63a, a PCR fragment containing the mouse DNp63a gene using murine pcDNA3-DNp63a as a template was subcloned into the retroviral vector pMSCV-puro (Clontech, Palo Alto, CA, USA) digested with BglII and HpaI. The DNp63a point mutant derivatives, C306R and C526W, were generated using QuikChange Site-Directed Mutagenesis Kit (Stratagene Inc., La Jolla, CA, USA). To construct pMSCV-CD82, the fragment containing the human CD82 gene from pcDNA3-CD82 65 was subcloned into the retroviral vector pMSCV-puro digested with BglII and XhoI. Lentivirus expressing a short hairpin RNA (shRNA) specific for CD82 or GSK3b were constructed using a pLKO.1 vector backbone (AddGene, Cambridge, MA, USA). Targeting shRNA sequences are listed in Supplementary  Table S4 . All constructs were confirmed by DNA sequencing.
For amplification and preparation of lentivirus, 293FT cells (5 Â 10 6 ) were cotransfected with 6 mg of psPAX2/pMD2.G (lentiviral packaging plasmids) and either 6 mg of a pLKO.1 shRNA plasmid or control using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Forty-eight hours after transfection, culture media were collected, filtered and subjected to ultracentrifugation at 25 000 r.p.m. for 90 min at 4 1C. Pellets were resuspended in 200 ml DMEM and aliquots were stored at À 80 1C. Cells in 6-well plates were infected with 50 ml of recombinant virus particles suspended in 1 ml culture media containing 10 mg/ml polybrene. Forty-eight hours postinfection, cells were selected by puromycin resistance (1 mg/ml for HaCaT, 2 mg/ml for MCF-10A and FaDu and 4 mg/ml for Hs-578T) for an additional 48 h before subsequent experiments. To amplify retrovirus, a process similar to lentivirus was used, except using the pol/gag/env retroviral packaging system for transfection.
b-Catenin small interfering RNA (siRNA) was designed and synthesized by Qiagen Inc. (Valencia, CA, USA). Cells were transfected with 200 nM siRNA using Lipofectamine 2000 in 60 mm cell culture dishes according to the manufacturer's instructions. Twelve to sixteen hours after transfection, media were changed to 5 ml normal growth media. Targeting siRNA sequences are listed in Supplementary  Table S4 .
Western blot analysis. Cells were lysed in RIPA buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM PMSF, 2 mg/ml leupeptin and 2 mg/ml aprotinin). Equal amounts of total protein (40-100 mg) were separated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (NEN LifeSciences, Waltham, MA, USA) and hybridized to an appropriate primary antibody and HRP-conjugated secondary antibody for subsequent detection by enhanced chemiluminescence (Amersham, Piscataway, NJ, USA). Specific antibodies for p63 (4A4), CD82 (C-16), E-cadherin (H-108), N-cadherin (13A9), b-actin (C-11) and p53 (DO-1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies specific for p21 (SXM-30) and b-catenin (610153) were purchased from BD Biosciences (San Jose, CA, USA). Antibodies for GSK3b (F9332) and vimentin (clone V9) were obtained from Cell Signaling (Danvers, MA, USA) and Lab Vision (Fremont, CA, USA), respectively. Goat anti-mouse IgG-HRP (sc-2005), goat anti-rabbit IgG-HRP (sc-2004) and donkey anti-goat IgG-HRP (sc-2020) secondary antibodies were obtained from Santa Cruz Biotechnology.
Q-PCR. Total RNA was extracted from cultured cells using TRIzol (Gibco, Life Technologies, Rockville, MD, USA) according to the manufacturer's instruction. RNA (5 mg) was reverse transcribed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen), followed by Q-PCR in 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using QuantiTect SYBR Green PCR Kit (Qiagen, Venlo, Netherlands). The reactions were carried out in a 96-well plate at 95 1C for 10 min, followed by 40 ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed by using EZ ChIP Kit (Upstate Biotechnology Inc., Waltham, MA, USA). Briefly, cells were crosslinked to chromatin with 1% formaldehyde for 10 min at 37 1C, the p63-DNA complexes were immunoprecipitated using antibodies against p63 (4A4) or anti-mouse IgG, recovered with protein A/G beads and treated with proteinase K to purify DNA. PCR was performed to amplify fragments of the CD82 promoter sequences. The primers targeting CD82 promoter are listed in Supplementary  Table S4 .
Assays for cell invasion and Matrigel outgrowth. Cell invasion was measured using 24-well, 8 mm polycarbonate transwell systems coated with Matrigel (BD Biosciences, San Jose, CA, USA). Briefly, Hs-578T (1.0 Â 10 5 ) or FaDu (2.0 Â 10 5 ) cells suspended in serum-free DMEM were seeded into the inner chamber, and DMEM containing 10% FBS was used as a chemoattractant in the outside chamber. Twenty-four hours after seeding, noninvasive cells were removed with a cotton swab, and invading cells were fixed and stained with 0.5% crystal violet in 70% ethanol for 10 min. Cells were counted in four random fields under a Zeiss light microscope (Carl Zeiss, Jena, Germany) at Â 100 magnification. Alternatively, stained cells were lyzed with 2% SDS buffer (in 1 Â PBS) and subjected to spectrophotometric analysis at 570 nm.
Matrigel outgrowth was measured in Matrigel-coated 96-well plates. For the bottom layer, 40 ml of 6.3 mg/ml Matrigel in serum-free DMEM was added into a 96-well tissue culture plate and incubated at 37 1C for 30 min to allow the Matrigel to solidify. Two microliters of Hs-578T cell suspension (1.0 Â 10 3 cells) in serum-free medium (DMEM) were mixed with ice-cold 40 ml Matrigel and plated onto the solidified bottom layer. The plates were then incubated at 37 1C for 30 min to allow the Matrigel to solidify. Growth medium was added into the wells and was replaced with fresh medium every 3 days. Following incubation at 37 1C for 5-7 days, cell morphology was photographed using a Zeiss Axiovert 200M light microscope (Carl Zeiss) at Â 100 magnification.
